AurimMed’s Announcements

October, 2016 Patent offices of Singapore and South Korea issued patent for AurimMed CNS-active compounds
December, 2015 The United States Patent and Trademark Office issued patent for AurimMed CNS-active compounds
November, 2015 The Mexican Patent Office issued Mexico patent for AurimMed CNS-active compounds
October, 2015 AurimMed presented its Parkinson and SMA results at Society for Neuroscience (Chicago, IL)
August, 2015 The in vivo test results suggest that oral treatment of AMP-X-0079 for two weeks significantly reduced the MPTP-induced abnormal involuntary hindlimb clasping and improved the grooming behavior and motor coordination in MPTP-lesioned mice. The immunohistochemical analyses suggested that oral AMP-X-0079 treatment for two weeks can effectively induce recovery effect from MPTP-induced lesion in the midbrain and the striatum
July, 2015 Monograph on AurimMed’s lead, AMP-X-0079, antiepileptic candidate published in NIHRed Book
June, 2015 AurimMed presented its SMA results at Cure SMA Research Annual meeting (Kansas City, MO)
May, 2015 Patent offices for Australia and Japan issued patent for AurimMed CNS-active compounds
February 2015 Patent Office of the People’s Republic of China issued patent for AurimMed CNS-active compounds
September, 2014 AurimMed presented its work at EILAT Conference XII (Madrid, Spain)
June, 2014 AurimMed presented its work at Epilepsy Pipeline Conference (San Francisco, CA)
March, 2014 Data obtained from Delaware State University collaboration showed AurimMed compounds have potent neuroprotective effects against oxidative stress (mediated by both H₂O₂and MPP+) in Parkinson’s Disease in vitro models.
March, 2014 AurimMed’s lead candidate, AMP-X-0079, is one of the very few compounds capable of terminating ongoing status epilepticus seizures due to a nerve agent and It controls seizure rapidly within, typically less than 15 min.
March, 2014 Research collaboration established with the Delaware State University, to investigate AurimMed compounds activity in tests for effectiveness in oxidative stress assays thought to model Parkinson’s disease (PD).
November, 2013 Renewal of Agreement (MTA) with Department of Defense (DOD)
October, 2013 Research collaboration with the Nemours Alfred I. DuPont Hospital for Children, demonstrates that AurimMed lead candidates have remarkable activity in tests for expression of SMN2, which is a current therapeutic target for treatment of Spinal Muscular Atrophy (SMA).
September, 2013 Research collaboration established with the Nemours Alfred I. DuPont Hospital for Children, to test AurimMed lead candidates for activity in in vitro assays related to therapeutic targets for Spinal Muscular Atrophy (SMA) (SMN2 expression)
September, 2013 NIH data establish that AMP-X-0079 prevents cognitive deficits, preserves spatial learning and memory, and provides neuroprotection in vivo.
July, 2013 AurimMed Pharma receives inaugural Epilepsy Innovation Seal of Excellence award from Epilepsy Foundation of America. http://www.epilepsy.com/etp/seal_of_excellence
December, 2012 AurimMed’s lead compound found effective by NIH-ASP in model of drug-resistant epilepsy.
- December, 2010 Monograph on AurimMed’s lead antiepileptic candidate published in NIHRed Book.
- November, 2009 Testing by U.S. Army Medical Research Institute of Chemical Defense (DOD) demonstrates AurimMed’s lead compound has significant activity in suppressing and eliminating severe seizures induced by Soman (a highly toxic nerve agent).
- October, 2009 Material Transfer Agreement (MTA) established with Department of Defense (DOD) for testing AurimMed’s compounds as chemical countermeasures in U.S. CounterACT Program.
- July, 2009 NIH testing demonstrates AurimMed compounds have significant analgesic activity against inflammatory and neuropathic pain.
- April, 2009 AurimMed presents its work on novel anticonvulsants at 10^th Antiepileptic Drug Trials Conference, Coral Gables, FL.
- January, 2009 AurimMed compounds found to be non-toxic in Cell Proliferation assays by Stem Cell Innovations^®, Inc.
- September, 2008 AurimMed antiepileptic compounds tested by Stem Cell Innovations^®, Inc. in Human Liver Cell assays showing that AurimMed’s compounds are not cell or liver toxic at high concentrations.
- July, 2008 NIH data demonstrate AurimMed’s lead candidates active against status epilepticus.
- July, 2007 Collaboration established with NIH Anticonvulsant ScreeningProgram (ASP).
- March, 2007 AurimMed Pharma established.

Report abuse